(:KIN)

Aug 27, 2021 04:45 pm ET
STOCKHOLDER ALERT: Monteverde & Associates Continues to Investigate the Following Merger
NEW YORK, Aug. 27, 2021 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating:
Jul 29, 2021 11:47 am ET
INVESTIGATION ALERT: Halper Sadeh LLP Investigates RFL, VNE, ACBI, KIN; Shareholders are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Rafael Holdings, Inc. (NYSE: RFL) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties...
Jul 29, 2021 10:32 am ET
Lifshitz Law Firm, P.C. Announces Investigation of BRBS, IRT, KIN, and MMAC
Blue Ridge Bankshares, Inc. (NYSE: BRBS) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale FVCB to BRBS. Under the terms of the merger agreement FVCB shareholders will received...
Jul 27, 2021 06:08 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates SYKE, TGRF, ONEM, KIN; Shareholders are Encouraged to Contact the Firm
NEW YORK, July 27, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Jul 21, 2021 09:06 am ET
Lifshitz Law Firm, P.C. Announces Investigation of BRBS, KIN, MMAC, and GRA
Blue Ridge Bankshares, Inc. (NYSE: BRBS) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale FVCB to BRBS. Under the terms of the merger agreement FVCB shareholders will received...
Jul 18, 2021 02:09 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates CORE, FCCY, KIN, MNR; Shareholders are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Core-Mark Holding Company, Inc. (NASDAQ: CORE) concerning potential violations of the federal securities laws and/or breaches of fiduciary...
Jul 16, 2021 09:00 pm ET
SHAREHOLDER ALERT: Monteverde & Associates Continues to Investigate the Following Merger
NEW YORK, July 16, 2021 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating:
Jul 15, 2021 03:55 pm ET
INVESTIGATION ALERT: Halper Sadeh LLP Investigates FCCY, CVA, KIN, IKNX; Shareholders are Encouraged to Contact the Firm
NEW YORK, July 15, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Jul 12, 2021 12:00 am ET
INVESTIGATION ALERT: Halper Sadeh LLP Investigates TGRF, KIN, GRA; Shareholders are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: TGR Financial, Inc. (OTCQX: TGRF) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties...
Jul 10, 2021 04:00 pm ET
Lifshitz Law Firm, P.C. Announces Investigation of ADXS, KIN, MMAC, and GRA
Advaxis, Inc. (NasdaqCM: ADXS) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the merger of ADXS with Biosight Ltd. If you are investor, and would like information about our...
Jul 08, 2021 02:55 pm ET
INVESTIGATION ALERT: Halper Sadeh LLP Investigates KIN, LDL, CAI, QADA, SNR; Shareholders are Encouraged to Contact the Firm
NEW YORK, July 8, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Jun 29, 2021 09:00 am ET
INVESTIGATION ALERT: Halper Sadeh LLP Investigates UFS, ALTA, FBNC, KIN; Shareholders are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Domtar Corporation (NYSE: UFS) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating...
Jun 28, 2021 06:02 pm ET
Lifshitz Law Firm, P.C. Announces Investigation of ICBK, KIN, MMAC, and SYKES
County Bancorp, Inc. (NasdaqGS: ICBK) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of ICBK to Nicolet Bankshares. If you are an investor, and would like additional...
Jun 28, 2021 09:00 am ET
SHAREHOLDER ALERT: Halper Sadeh LLP Investigates CAI, BOCH, SYKE, KIN; Shareholders are Encouraged to Contact the Firm
NEW YORK, June 28, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Jun 23, 2021 12:01 pm ET
SHAREHOLDER ALERT: WeissLaw LLP Reminds KIN, FMBI, SLCT, and CNST Shareholders About Its Ongoing Investigations
If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq.WeissLaw LLP1500 Broadway, 16th...
Jun 22, 2021 02:59 pm ET
Moore Kuehn Encourages KIN, SVOK, ROCR, and DCRC Investors to Contact Law Firm
NEW YORK, June 22, 2021 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies:
Jun 21, 2021 01:24 pm ET
KINDRED BIOSCIENCES INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kindred Biosciences, Inc. - KIN
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Kindred Biosciences, Inc. (NasdaqGS: KIN) to Elanco Animal Health Incorporated (NYSE: ELAN). Under the terms of the proposed transaction, shareholders of Kindred will receive only $9.25 for each share of Kindred that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Jun 21, 2021 09:00 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Companies - KIN, SYKE, USCR, ONEM, QTS, MCF
NEW YORK, June 21, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Jun 17, 2021 11:37 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates KIN, CNST, MDP, FMBI; Shareholders are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Kindred Biosciences, Inc. (NASDAQ: KIN) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties...
Jun 16, 2021 07:30 pm ET
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Kindred Biosciences, Inc. - KIN
NEW YORK, June 16, 2021 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Kindred Biosciences, Inc. ("KIN" or the "Company") (KIN) relating to its proposed acquisition by Elanco Animal Health, Inc. KIN shareholders will receive $9.25 in cash per share they own.
Jun 16, 2021 06:45 pm ET
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Kindred Biosciences, Inc.
NEW YORK, June 16, 2021 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Kindred Biosciences, Inc. (NASDAQ: KIN) and its board of directors concerning the proposed acquisition of the company by Elanco Animal Health Incorporated (NYSE: ELAN). Stockholders will receive $9.25 for each share of Kindred Biosciences stock that they hold. The transaction is valued at approximately $440 million and is expected to close in the third quarter of 2021.
Jun 16, 2021 01:58 pm ET
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Kindred Biosciences, Inc. Buyout
Rigrodsky Law, P.A. announces that it is investigating Kindred Biosciences, Inc. (“Kindred”) (NASDAQ CM: KIN) regarding possible breaches of fiduciary duties and other violations of law related to Kindred’s agreement to be acquired by Elanco Animal...
Jun 16, 2021 12:14 pm ET
SHAREHOLDER ALERT: WeissLaw LLP Investigates Kindred Biosciences, Inc.
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Kindred Biosciences, Inc. (“Kindred” or the “Company”) (NASDAQ: KIN) in connection with the proposed acquisition of the...
Jun 16, 2021 11:41 am ET
KINDRED BIOSCIENCES ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of KIN and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Kindred Biosciences, Inc. (NASDAQ: KIN) (“KindredBio”) breached their fiduciary duties or violated the...
Jun 16, 2021 10:50 am ET
Kindred Biosciences Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Kindred Biosciences, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the F
Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Kindred Biosciences, Inc. (NASDAQ: KIN) to Elanco Animal Health Incorporated for $9.25 per share is fair to Kindred Biosciences shareholders.
Jun 16, 2021 10:50 am ET
Thinking about buying stock in Kindred Biosciences, Applied UV, Sundial Growers, Vista Gold, or Arcadia Biosciences?
NEW YORK, June 16, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for KIN, AUVI, SNDL, VGZ, and RKDA.
Jun 16, 2021 06:30 am ET
Elanco Announces Agreement to Acquire Kindred Biosciences
Elanco Animal Health Incorporated (NYSE: ELAN) and Kindred Biosciences, Inc. (KindredBio, NASDAQ: KIN) today announced the parties have entered into a definitive agreement for Elanco to acquire KindredBio, a biopharmaceutical company focused on developing novel pet therapeutics based on validated human targets. The acquisition further accelerates Elanco’s expansion in the attractive pet health market, particularly advancing Elanco’s presence in the fast-growing billion-dollar dermatology category.
Jun 16, 2021 06:30 am ET
Elanco Announces Agreement to Acquire Kindred Biosciences
GREENFIELD, Ind. and SAN FRANCISCO, June 16, 2021 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) and Kindred Biosciences, Inc. (KindredBio, NASDAQ: KIN) today announced the parties have entered into a definitive agreement for Elanco to acquire KindredBio, a biopharmaceutical company focused on developing novel pet therapeutics based on validated human targets. The acquisition further accelerates Elanco's expansion in the attractive pet health market, particularly advancing Elanco's presence in the fast-growing billion-dollar dermatology category.
Feb 25, 2021 07:01 am ET
Kindred Biosciences Announces Submission of Parvovirus Monoclonal Antibody Data for Prophylactic Indication
SAN FRANCISCO, Feb. 25, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has submitted efficacy data to support the prophylactic indication for KIND-030 to the United States Department of Agriculture (USDA) Center for Veterinary Biologics for review. This submission is part of the overall project data package that will be submitted and evaluated for full approval. KIND-030 is a monoclonal antibody targeting canine parvovirus.
Feb 16, 2021 03:02 pm ET
Kindred Biosciences to Present at the BofA Securities Animal Health Virtual Summit
SAN FRANCISCO, Feb. 16, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will present at the BofA Securities Animal Health Virtual Summit on February 25.   
Feb 09, 2021 07:32 am ET
Kindred Biosciences Announces Two New Appointments to Board of Directors
SAN FRANCISCO, Feb. 9, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has appointed Lyndon Lien, Ph.D., an experienced biotech CEO, entrepreneur and investor, and Nanxi Liu, CEO and Co-Founder of Enplug and Co-Founder of Nanoly Bioscience, to its Board of Directors, effective February 5, 2021.
Dec 22, 2020 07:31 am ET
Kindred Biosciences Initiates Pivotal Efficacy Study of Tirnovetmab (Interleukin-31) Monoclonal Antibody for Canine Atopic Dermatitis
SAN FRANCISCO, Dec. 22, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has initiated the pivotal efficacy study for tirnovetmab (KIND-016), a fully caninized, high-affinity monoclonal antibody targeting interleukin (IL)-31 for the treatment of atopic dermatitis in dogs.
Dec 21, 2020 07:31 am ET
Kindred Biosciences Announces Positive Results from Pilot Field Effectiveness Study for Anti-TNFα Antibody for Canine Inflammatory Bowel Disease
SAN FRANCISCO, Dec. 21, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive results from the pilot field effectiveness study of its monoclonal antibody against tumour necrosis factor alpha (anti-TNFα antibody) for canine inflammatory bowel disease (IBD).
Dec 11, 2020 07:00 am ET
Kindred Biosciences Announces Agreement Granting Elanco Exclusive Global Rights for its Parvovirus Monoclonal Antibody
SAN FRANCISCO, Dec. 11, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced an agreement granting Elanco Animal Health Incorporated exclusive global rights to KIND-030, a monoclonal antibody targeting canine parvovirus (CPV). As part of the agreement, KindredBio also has a right of last refusal to manufacture certain of Elanco's other monoclonal antibody products.  
Dec 02, 2020 03:02 pm ET
Kindred Biosciences to Present at Guggenheim Animal Health Summit
SAN FRANCISCO, Dec. 2, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that Dr. Richard Chin, Chief Executive Officer, will present on the "How Biologics Will Change Veterinary Practices" panel at the Guggenheim Animal Health Summit at 10am ET on Monday, December 7, 2020.
Nov 11, 2020 07:32 am ET
Kindred Biosciences to Participate in Stifel Virtual Healthcare Conference and A.G.P. Virtual Healthcare Symposium
SAN FRANCISCO, Nov. 11, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will present at the Stifel Virtual Healthcare Conference on November 17 and participate in the A.G.P. Virtual Healthcare Symposium on November 19.  
Nov 09, 2020 03:02 pm ET
Kindred Biosciences Announces Third Quarter 2020 Financial Results
SAN FRANCISCO, Nov. 9, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the third quarter ended September 30, 2020 and provided updates on its programs. For the third quarter of 2020, KindredBio reported net revenues of $1.0 million and a net loss of $12.2 million, or $0.31 per share.
Oct 28, 2020 04:05 pm ET
Kindred Biosciences to Announce Third Quarter 2020 Financial Results
SAN FRANCISCO, Oct. 28, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will release its third quarter 2020 financial results on November 9, 2020, after the market close. The Company will host a conference call at 4:30 p.m. Eastern time/1:30 p.m. Pacific time that day.
Aug 31, 2020 05:00 pm ET
LD Micro - 360 Companies - Set to Present this Week
LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
Aug 05, 2020 04:02 pm ET
Kindred Biosciences Announces Second Quarter 2020 Financial Results
SAN FRANCISCO, Aug. 5, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the second quarter ended June 30, 2020 and provided updates on its programs. For the second quarter of 2020, KindredBio reported net revenues of $39.6 million and net income of $24.0 million, or $0.60 per share (diluted), which includes a non-recurring charge of $2.3 million.
Aug 05, 2020 09:00 am ET
LD Micro - Announces Preliminary List of Presenters for the LD 500
LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
Jul 23, 2020 08:32 am ET
Kindred Biosciences to Announce Second Quarter 2020 Financial Results
SAN FRANCISCO, July 23, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will release its second quarter 2020 financial results on August 5, 2020, after the market close. The Company will host a conference call at 4:30 p.m. Eastern time/1:30 p.m. Pacific time that day.
Jul 16, 2020 11:00 am ET
'Zooming with LD' to Feature 10 Distinct Companies July 20th-31st
LOS ANGELES, CA / ACCESSWIRE / July 16, 2020 / LD Micro today announced that it will be hosting ten companies over the final two weeks of July, with a group presentation in the morning, followed by private investor meetings throughout the day.
Jun 08, 2020 04:02 pm ET
Kindred Biosciences Announces Plan to Strengthen its Strategic Position
SAN FRANCISCO, June 8, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced a plan to enhance its strategic position. The company will prioritize its most attractive late stage programs and substantially reduce expenses to best position it for success with the previously announced business model.
May 20, 2020 07:58 am ET
Kindred Biosciences Announces COVID-19 Vaccine Manufacturing Agreement with Vaxart
SAN FRANCISCO, May 20, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company developing novel biologics, today announced it has entered into an agreement with Vaxart, Inc. (Nasdaq: VXRT) for the manufacture of Vaxart's oral vaccine candidate for COVID-19.
May 13, 2020 08:30 am ET
Kindred Biosciences to Present at Stifel 2020 Virtual Jaws & Paws Conference
SAN FRANCISCO, May 13, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will present at the Stifel 2020 Virtual Jaws & Paws Conference on May 27.  
May 07, 2020 04:02 pm ET
Kindred Biosciences Announces First Quarter 2020 Financial Results
SAN FRANCISCO, May 7, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the first quarter ended March 31, 2020 and provided updates on its programs. For the first quarter 2020, KindredBio reported net product revenues of $0.6 million and a net loss of $22.8 million, or $0.58 per share, which includes non-recurring charges of $5.1 million.
Apr 23, 2020 08:32 am ET
Kindred Biosciences to Announce First Quarter 2020 Financial Results
SAN FRANCISCO, April 23, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will release its first quarter 2020 financial results on May 7, 2020, after the market close. The Company will host a conference call at 4:30 p.m. Eastern time/1:30 p.m. Pacific time that day.
Apr 15, 2020 04:02 pm ET
Kindred Biosciences Announces Completion of Mirataz® (mirtazapine transdermal ointment) Transaction
SAN FRANCISCO, April 15, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has completed the sale of Mirataz® to Dechra Pharmaceuticals PLC (LSE: DPH) for an upfront payment of $43 million, and royalties on worldwide sales.
Mar 24, 2020 08:31 am ET
Kindred Biosciences Announces Positive Results from Pilot Field Efficacy Study of its IL-4/IL-13 SINK Molecule Being Developed for the Treatment of Atopic Dermatitis in Dogs
SAN FRANCISCO, March 24, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive results from its pilot field efficacy study of KIND-025, a canine fusion protein targeting interleukin-4 (IL-4) and interleukin-13 (IL-13), for the treatment of atopic dermatitis in dogs.
Mar 16, 2020 04:02 pm ET
Kindred Biosciences Announces Mirataz® (mirtazapine transdermal ointment) Transaction and Reports Fourth Quarter and Full Year 2019 Financial Results
SAN FRANCISCO, March 16, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has entered into a transaction for the sale of Mirataz® to Dechra Pharmaceuticals PLC (LSE: DPH) for an upfront payment of $43 million and royalties on worldwide sales.
Nov 14, 2019 03:05 pm ET
Kindred Biosciences to Participate in Stifel Healthcare Conference and Jefferies London Healthcare Conference
SAN FRANCISCO, Nov. 14, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will participate in the Stifel Healthcare Conference on November 19 in New York City and Jefferies London Healthcare Conference on November 21.
Nov 12, 2019 03:01 pm ET
Kindred Biosciences Announces Third Quarter 2019 Financial Results
SAN FRANCISCO, Nov. 12, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the third quarter ended September 30, 2019 and provided updates on its programs. For the third quarter 2019, KindredBio reported net product revenues of $1.1 million and a net loss of $15.3 million, or $0.39 per share.
Oct 28, 2019 08:31 am ET
Kindred Biosciences to Announce Third Quarter 2019 Financial Results
SAN FRANCISCO, Oct. 28, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will release its third quarter 2019 financial results on November 12, 2019, after the market close. The Company will host a conference call at 4:30 p.m. Eastern time/1:30 p.m. Pacific time that day.
Oct 10, 2019 04:02 pm ET
Kindred Biosciences Announces Positive Opinion from CVMP in the European Union for Mirataz® (mirtazapine transdermal ointment) for Cats Experiencing Poor Appetite and Weight Loss
SAN FRANCISCO, Oct. 10, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (Nasdaq: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced that the European Medicines Agency's Committee for Medicinal Products for Veterinary Use (CVMP) has adopted a positive opinion recommending marketing authorization of Mirataz® (mirtazapine transdermal ointment) for bodyweight gain in cats experiencing poor appetite and weight loss resulting from chronic medical conditions. Furthermore, KindredBio announced that it recently filed for regulatory app
Oct 02, 2019 07:01 am ET
Kindred Biosciences Secures $50 Million Debt Facility with Solar Capital Partners
SAN FRANCISCO, Oct. 2, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (Nasdaq: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced the closing of a $50 million senior secured debt facility with investment affiliates managed by Solar Capital Partners, LLC.
Sep 27, 2019 02:51 am ET
Unibet Takes on its Second U.S. Market
VALLETTA, Malta, Sept. 27, 2019 /PRNewswire/ -- Kindred Group´s flagship brand Unibet takes on its second U.S. Market in Pennsylvania and announces today its official launch into Pennsylvania with the opening of its Sportsbook in partnership with Mohegan Sun Pocono - marking the company's second U.S. market entry in just one month.
Sep 10, 2019 07:01 am ET
Kindred Biosciences Awarded a Contract by the National Cancer Institute in Support of the PREVENT Cancer Program
SAN FRANCISCO, Sept. 10, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company developing novel drugs and biologics, today announced that it has been selected by the National Cancer Institute (NCI) as one of three contractors in response to the solicitation for the PREVENT Cancer Preclinical Drug Development Program (PREVENT): Current Good Manufacturing Practice (cGMP) Production of Vaccines and Biologicals for Cancer Prevention (cGMP Pool). As a cGMP pool contractor, KindredBio is eligible to provide manufacturing, formulation and analyti
Aug 28, 2019 08:31 am ET
Kindred Biosciences to Participate in H.C. Wainwright Global Investment Conference, Lake Street Best Ideas Growth Conference, and Cantor Global Healthcare Conference
SAN FRANCISCO, Aug. 28, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will participate in the H.C. Wainwright Global Investment Conference on September 10, the Lake Street Best Ideas Growth Conference on September 12, and the Cantor Global Healthcare Conference on October 2, in New York City.
Aug 01, 2019 04:01 pm ET
Kindred Biosciences Announces Second Quarter 2019 Financial Results and Unveils Positive Results from Pilot Efficacy Study of Parvovirus Monoclonal Antibody
SAN FRANCISCO, Aug. 1, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the second quarter ended June 30, 2019 and provided updates on its programs, including positive results from a pilot efficacy study of its previously undisclosed parvovirus monoclonal antibody. For the second quarter 2019, KindredBio reported net product revenues of $1.2 million and a net loss of $14.3 million, or $0.37 per share. For the first six months of 2019, net product
Jul 29, 2019 07:01 am ET
Kindred Biosciences Announces Positive Results from Pilot Field Effectiveness Study of its Interleukin-31 Monoclonal Antibody for the Treatment of Atopic Dermatitis in Dogs
SAN FRANCISCO, July 29, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced positive topline results from its pilot effectiveness study of KIND-016, a fully caninized, high-affinity monoclonal antibody targeting interleukin-31 (IL-31), for the treatment of atopic dermatitis in dogs. Atopic dermatitis is the most common reason owners take their dog to the veterinarian, and is estimated to affect 10 - 15% of dogs worldwide.1 The current market size is over $600 million annu
Jul 16, 2019 08:31 am ET
Kindred Biosciences to Announce Second Quarter 2019 Financial Results
SAN FRANCISCO, July 16, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will release its second quarter 2019 financial results on August 1, 2019, after the market close. The Company will host a conference call at 4:30 p.m. Eastern time/1:30 p.m. Pacific time that day.
May 13, 2019 08:31 am ET
Kindred Biosciences to Participate in the B. Riley FBR Institutional Investor Conference, Stifel 2019 Dental & Veterinary Conference and 9th Annual LD Micro Invitational
SAN FRANCISCO, May 13, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will participate in the B. Riley FBR Institutional Investor Conference taking place May 22nd in Beverly Hills, the Stifel 2019 Dental & Veterinary Conference taking place May 29th in New York, and the 9th Annual LD Micro Invitational taking place June 4th in Bel-Air, CA.
May 09, 2019 04:01 pm ET
Kindred Biosciences Announces First Quarter 2019 Financial Results
SAN FRANCISCO, May 9, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the first quarter ended March 31, 2019 and provided updates on its programs. For the first quarter 2019, KindredBio reported net product revenues of $0.5 million and a net loss of $16.1 million, or $0.42 per share.
Apr 25, 2019 08:01 am ET
Kindred Biosciences to Announce First Quarter 2019 Financial Results
SAN FRANCISCO, April 25, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will release its first quarter 2019 financial results on May 9, 2019 after the market close. The Company will host a conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time that day.
Apr 11, 2019 08:40 am ET
Consolidated Research: 2019 Summary Expectations for ZIOPHARM Oncology, Airgain, Liquidity Services, Kindred Biosciences, Landmark Infrastructure Partners LP, and Sensus Healthcare — Fundamental Analy
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of ZIOPHARM Oncology Inc (NASDAQ:ZIOP), Airgain, Inc. (NASDAQ:AIRG), Liquidity...
Mar 06, 2019 03:01 pm ET
Kindred Biosciences Announces Fourth Quarter and Full Year 2018 Financial Results
SAN FRANCISCO, March 6, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the fourth quarter and full year ended December 31, 2018 and provided updates on its programs. For the fourth quarter 2018, KindredBio reported net product revenues of $1.3 million and a net loss of $15.4 million, or $0.46 per share. For the full year 2018, net product revenues were $2.0 million and the net loss was $49.7 million, or $1.60 per share.
Feb 19, 2019 07:31 am ET
Kindred Biosciences to Announce Fourth Quarter and Year-End 2018 Financial Results
SAN FRANCISCO, Feb. 19, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will release its fourth quarter and year-end 2018 financial results on March 6, 2019 after the market close. The Company will host a conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time that day.
Feb 13, 2019 07:31 am ET
Kindred Biosciences to Present at Bank of America Merrill Lynch Animal Health Summit and Barclays Global Healthcare Conference
SAN FRANCISCO, Feb. 13, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will present at the Bank of America Merrill Lynch (BAML) Animal Health Summit on February 25 in New York City and at the Barclays Global Healthcare Conference on March 12 in Miami.
Jan 23, 2019 03:10 pm ET
Kindred Biosciences Announces Closing of Public Offering of Common Stock and the Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN FRANCISCO, Jan. 23, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, announced that it has closed its public offering of 4,847,250 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase 632,250 additional shares of KindredBio's common stock, at $9.50 per share, less underwriting discounts and commissions. The gross proceeds to KindredBio are approximately $46 million before deducting underwriting discounts and commissions and of
Jan 22, 2019 07:31 am ET
Kindred Biosciences Named Best Company in North America by Leading Industry Publication
SAN FRANCISCO, Jan. 22, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has been named Best Company in North America by Animal Pharm, a leading industry publication.
Jan 18, 2019 08:31 am ET
Kindred Biosciences Announces Pricing of Public Offering
SAN FRANCISCO, Jan. 18, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced the pricing of an underwritten public offering of 4,215,000 shares of its common stock at a public offering price of $9.50 per share, for a total offering amount of $40,042,500 before deducting underwriting discounts and commissions and estimated offering expenses payable by KindredBio.  KindredBio has granted to the underwriters a 30-day option to purchase up to an additional 632,250 shares of it
Jan 17, 2019 03:01 pm ET
Kindred Biosciences Announces Proposed Public Offering of Common Stock
SAN FRANCISCO, Jan. 17, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial stage biopharmaceutical company focused on saving and improving the lives of pets, today announced a proposed public offering of its common stock. All of the common stock is being offered by KindredBio. In addition, KindredBio intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance a
Jan 14, 2019 06:01 am ET
Kindred Biosciences Announces Positive Results from Pilot Field Effectiveness Study of epoCat™ for the Management of Non-Regenerative Anemia in Cats and Availability of Mirataz® at Banfield Pet Hospit
SAN FRANCISCO, Jan. 14, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced positive topline results from its pilot field effectiveness study of epoCat (KIND-510a), a long-acting feline recombinant erythropoietin that is being developed for the management of anemia in cats.
Nov 16, 2018 08:35 am ET
Recent Analysis Shows Spirit Airlines, Cactus, Evergy, ADDvantage Technologies Group, Kindred Biosciences, and Farfetch Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Spirit Airlines, Inc. (NYSE:SAVE), Cactus, Inc. (NYSE:WHD), Evergy Inc....
Nov 07, 2018 03:01 pm ET
Kindred Biosciences Announces Third Quarter 2018 Financial Results
SAN FRANCISCO, Nov. 7, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the third quarter ended September 30, 2018 and provided updates on its programs. For the third quarter 2018, KindredBio reported net product revenues of $0.6 million and a net loss of $13.0 million or $0.39 per share.
Oct 30, 2018 04:01 pm ET
Kindred Biosciences Announces Positive Results from Pilot Effectiveness Study of its Fully Caninized IL-31 Antibody for the Treatment of Atopic Dermatitis in Dogs and Issuance of U.S. Patent
SAN FRANCISCO, Oct. 30, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced positive topline results from its pilot effectiveness study of KIND-016, a fully caninized, high-affinity monoclonal antibody targeting interleukin-31 (IL-31), for the treatment of atopic dermatitis in dogs. Atopic dermatitis is the leading reason owners take their dog to the veterinarian, and the current market size is over $500 million annually and growing rapidly.
Oct 24, 2018 08:31 am ET
Kindred Biosciences to Announce Third Quarter 2018 Financial Results
SAN FRANCISCO, Oct. 24, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will release its third quarter 2018 financial results on November 7, 2018 after the market close. The Company will host a conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time that day.
Oct 23, 2018 07:31 am ET
Kindred Biosciences Elects Denise Bevers to its Board of Directors and Promotes Her to President
SAN FRANCISCO, Oct. 23, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced that Denise Bevers, Co-Founder and Chief Operating Officer of KindredBio, has been elected to its Board of Directors and promoted to President.
Sep 17, 2018 08:31 am ET
Kindred Biosciences to Present at Cantor Global Healthcare Conference and Ladenburg Thalmann 2018 Healthcare Conference
SAN FRANCISCO, Sept. 17, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will present at the Cantor Global Healthcare Conference on October 1 and the Ladenburg Thalmann 2018 Healthcare Conference on October 2, 2018 in New York City.
Aug 30, 2018 08:31 am ET
Kindred Biosciences to Participate in the CL King 16th Annual Best Ideas Conference, Lake Street Capital Markets 2nd Annual Best Ideas Growth Conference and LD Micro San Francisco Summit
SAN FRANCISCO, Aug. 30, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will participate in the LD Micro San Francisco Summit taking place September 4th, the CL King 16th Annual Best Ideas Conference and the Lake Street Capital Markets 2nd Annual Best Ideas Growth Conference, both taking place September 13th in New York.
Aug 21, 2018 08:31 am ET
Kindred Biosciences to Participate in the B. Riley FBR Annual Healthcare Conference
SAN FRANCISCO, Aug. 21, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will participate in the B. Riley FBR Annual Healthcare Conference being held on September 4th in New York at the New York Marriott East Side.
Aug 09, 2018 04:01 pm ET
Kindred Biosciences Announces Second Quarter 2018 Financial Results
SAN FRANCISCO, Aug. 9, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the second quarter ended June 30, 2018 and provided updates on its programs.  
Jul 16, 2018 08:31 am ET
Kindred Biosciences to Announce Second Quarter 2018 Financial Results
SAN FRANCISCO, July 16, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will release its second quarter 2018 financial results on August 9, 2018 after the market close. The Company will host a conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time that day.
Jul 09, 2018 08:31 am ET
Kindred Biosciences Announces Commercial Availability of Mirataz® (mirtazapine transdermal ointment) to Veterinarians in the United States
SAN FRANCISCO, July 9, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced that Mirataz® (mirtazapine transdermal ointment) for the management of weight loss in cats is commercially available to veterinarians in the United States.
Jun 25, 2018 09:01 am ET
Kindred Biosciences Announces Exercise of Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
SAN FRANCISCO, June 25, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, announced the underwriters have exercised in full their option to purchase an additional 694,736 shares of KindredBio's common stock at $9.50 per share, less underwriting discounts and commissions. KindredBio also announced that it has closed its public offering of 5,326,314 shares of common stock at a public offering price of $9.50 per share, which included the sale of the shares pursuant to the option to purcha
Jun 20, 2018 04:01 pm ET
Kindred Biosciences Announces the Termination of Its At-The-Market Equity Offering Program
SAN FRANCISCO, June 20, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced the termination of its "at-the-market" equity offering program (the "ATM Facility") with B. Riley FBR, Inc. and Oppenheimer & Co. Inc. as sales agents.
Jun 20, 2018 09:10 am ET
Kindred Biosciences Announces Pricing of Public Offering
SAN FRANCISCO, June 20, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced the pricing of an underwritten public offering of 4,631,578 shares of its common stock at a public offering price of $9.50 per share, for a total offering amount of $44 million before deducting underwriting discounts and commissions and estimated offering expenses payable by KindredBio. KindredBio has granted to the underwriters a 30-day option to purchase up to an additional 694,736 shares of its
Jun 19, 2018 04:01 pm ET
Kindred Biosciences Announces Proposed Public Offering of Common Stock
SAN FRANCISCO, June 19, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced a proposed public offering of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
May 30, 2018 07:02 am ET
KindredBio Announces Positive Results from Pilot Effectiveness Study of KIND-014 for the Treatment of Gastric Ulcers in Horses
SAN FRANCISCO, May 30, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced positive results from its pilot field effectiveness study of KIND-014 for the treatment of gastric ulcers in horses.
May 29, 2018 08:02 am ET
Kindred Biosciences to Present at Jefferies 2018 Global Healthcare Conference and 8th Annual LD Micro Invitational Conference
SAN FRANCISCO, May 29, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will present at the 8th Annual LD Micro Invitational Conference taking place June 4th-6th in Bel Air, CA and at the Jefferies 2018 Global Healthcare Conference taking place June 5th-8th in New York.
May 24, 2018 07:02 am ET
Kindred Biosciences to Present at Stifel 2018 Dental & Veterinary Conference
SAN FRANCISCO, May 24, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will present at the Stifel 2018 Dental & Veterinary Conference on May 30, 2018 in New York City.
May 08, 2018 04:01 pm ET
Kindred Biosciences Announces First Quarter 2018 Financial Results
SAN FRANCISCO, May 8, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the first quarter ended March 31, 2018 and provided updates on its programs.  
May 07, 2018 07:00 am ET
Kindred Biosciences Receives FDA Approval of Mirataz™ (mirtazapine transdermal ointment) for the Management of Weight Loss in Cats
SAN FRANCISCO, May 7, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that the U.S. Food and Drug Administration's Center for Veterinary Medicine approved Mirataz (mirtazapine transdermal ointment) for the management of weight loss in cats. 
Apr 25, 2018 04:02 pm ET
Kindred Biosciences Announces the Appointment of Dr. Ernest Mario and Dr. Joseph McCracken to its Board of Directors
SAN FRANCISCO, April 25, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the appointment of Ernest Mario, Ph.D. and Joseph McCracken, D.V.M. to its Board of Directors.
Apr 24, 2018 04:02 pm ET
Kindred Biosciences Provides Updates on Pending Drug Approvals
SAN FRANCISCO, April 24, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has received a response from the Food and Drug Administration (FDA) for the Chemistry, Manufacturing, and Controls technical section for Zimeta IV for the control of fever in horses. The FDA has no additional questions or requests for KindredBio regarding this submission. The FDA stated that the approval is pending the pre-approval inspection, or PAI, at the contract manufacturer of Zimeta IV scheduled fo
Apr 18, 2018 04:01 pm ET
Kindred Biosciences to Announce First Quarter 2018 Financial Results
SAN FRANCISCO, April 18, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will release its first quarter 2018 financial results on May 8, 2018 after the market close. The Company will host a conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time that day.
Mar 08, 2018 03:01 pm ET
Kindred Biosciences to Present at the Oppenheimer 28th Annual Healthcare Conference
SAN FRANCISCO, March 8, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will present at the Oppenheimer 28th Annual Healthcare Conference on March 20-21, 2018 in New York City.
Mar 01, 2018 03:01 pm ET
Kindred Biosciences Announces Fourth Quarter and Full Year 2017 Financial Results
SAN FRANCISCO, March 1, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the fourth quarter and full year ended December 31, 2017 and provided updates on its programs.  
Feb 15, 2018 07:30 am ET
Kindred Biosciences to Announce Fourth Quarter and Year-End 2017 Financial Results
SAN FRANCISCO, Feb. 15, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will release its fourth quarter and year-end 2017 financial results on March 1, 2018 after the market close. The Company will host a conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time that day.
Feb 13, 2018 07:30 am ET
Kindred Biosciences to Participate in the Bank of America Merrill Lynch Animal Health Summit
SAN FRANCISCO, Feb. 13, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will participate in the Bank of America Merrill Lynch Animal Health Summit on February 26, 2018 in New York City.
Dec 21, 2017 07:02 am ET
KindredBio Announces Submission of European Medicines Agency Filing for Mirataz™
SAN FRANCISCO, Dec. 21, 2017 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that the European Marketing Authorization application for Mirataz™ (mirtazapine transdermal gel) has been submitted to the European Medicines Agency (EMA). The EMA has accepted the submission for review, with the official acceptance date of December 21, 2017.
Nov 07, 2017 04:01 pm ET
Kindred Biosciences Announces Third Quarter 2017 Financial Results
SAN FRANCISCO, Nov. 7, 2017 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the third quarter ended September 30, 2017 and provided updates on its programs.  
Oct 11, 2017 10:01 am ET
Kindred Biosciences to Announce Third Quarter 2017 Financial Results
SAN FRANCISCO, Oct. 11, 2017 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will release its third quarter 2017 financial results on November 7, 2017 after the market close. The Company will host a conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time that day.
Oct 05, 2017 05:01 pm ET
Kindred Biosciences to Participate in the Oppenheimer & Co. Specialty Pharmaceuticals Conference
SAN FRANCISCO, Oct. 5, 2017 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that Denise Bevers, Co-Founder and Chief Operating Officer, will participate in the Oppenheimer & Co. Specialty Pharmaceuticals Conference, being held on October 11, 2017 in New York City. The event will feature one-on-one meetings at which investors will have the opportunity to meet with management to discuss key therapeutic programs in development and upcoming milestones.
Sep 11, 2017 10:00 am ET
Kindred Biosciences Announces Plans for Promotion of Dr. Zhan and Retirement of Dr. Sundlof
SAN FRANCISCO, Sept. 11, 2017 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that Dr. Stephen Sundlof will retire in January of 2018 and that, simultaneous with his retirement, Dr. Hangjun Zhan will be promoted to the position of Chief Scientific Officer.
Aug 30, 2017 10:02 am ET
Kindred Biosciences to Present at Upcoming Investor Conferences
SAN FRANCISCO, Aug. 30, 2017 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will be presenting at three, upcoming investor conferences in September 2017:
Aug 07, 2017 05:01 pm ET
Kindred Biosciences Announces Second Quarter 2017 Financial Results
SAN FRANCISCO, Aug. 7, 2017 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the second quarter ended June 30, 2017 and provided updates on its programs.  
Aug 04, 2017 10:02 am ET
Kindred Biosciences Sponsors Veterinary Students to Attend the 2017 American Association of Feline Practitioners Meeting
SAN FRANCISCO, Aug. 4, 2017 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will be sponsoring twenty veterinary students to attend the 2017 American Association of Feline Practitioners (AAFP) meeting to be held in Denver, CO October 19-22, 2017. Applicants included students from accredited veterinary colleges in the U.S. This sponsorship gives feline-focused veterinary students, who otherwise might not have the opportunity to attend, a chance to deepen their understanding and expo
Aug 01, 2017 08:34 am ET
Liolios 6th Annual Gateway Conference to Showcase 100 Companies at the Four Seasons San Francisco on September 6-7
SAN FRANCISCO, Aug. 01, 2017 (GLOBE NEWSWIRE) -- Liolios’ Gateway Conference is back for its 6th year and will showcase approximately 100 public and private companies at the Four Seasons in San Francisco on September 6-7, 2017....
Jul 24, 2017 10:01 am ET
Kindred Biosciences to Announce Second Quarter 2017 Financial Results
SAN FRANCISCO, Calif., July 24, 2017 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will release its second quarter 2017 financial results on August 7, 2017 after the market close. The Company will host a conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time that day.
Jul 12, 2017 09:40 am ET
KindredBio Announces Pricing of Public Offering
SAN FRANCISCO, July 12, 2017 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the pricing of an underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $7.50 per share, for a total offering amount of $22.5 million before deducting underwriting discounts and commissions and estimated offering expenses payable by KindredBio.  KindredBio has granted to the underwriters a 30-day option to purchase up to an additional 450,000 shares of its common stock.
Jul 11, 2017 05:10 pm ET
KindredBio Announces Proposed Public Offering of Common Stock
SAN FRANCISCO, July 11, 2017 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced a proposed public offering of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Jun 26, 2017 08:30 am ET
Kindred Biosciences Announces Acquisition of Kansas Manufacturing Plant and Execution of Commercial Manufacturing Agreement for Zimeta
SAN FRANCISCO, June 26, 2017 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has acquired a manufacturing facility in Elwood, Kansas. The purchase of this property, formerly owned by Boehringer Ingelheim and by Strategic Veterinary Pharmaceuticals, Inc., includes approximately 8 acres of land and two buildings encompassing approximately 180,000 square feet with clean rooms, utility, equipment, and related quality documentation suitable for small molecule and biologics manufacturing
Jun 15, 2017 09:01 am ET
Kindred Biosciences Added to the Russell 2000 Index
SAN FRANCISCO, June 15, 2017 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will join the US small-cap Russell 2000® Index, effective after the US market closes on June 23, according to a preliminary list of additions and the market capitalization cutoff posted June 14 as part of the 2017 Russell indexes reconstitution. Membership in the Russell 2000® Index, which remains in place for one year, is based on membership in the broad-market Russell 3000® Index. The Company will also b
May 30, 2017 10:01 am ET
Kindred Biosciences to Present Data from Six Studies at the 2017 American College of Veterinary Internal Medicine Conference
SAN FRANCISCO, May 30, 2017 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will be presenting data from six studies at the 2017 American College of Veterinary Internal Medicine (ACVIM) conference in National Harbor, MD, held June 8-10, 2017.  The Company will be sharing effectiveness and safety data from its Mirataz™ (mirtazapine transdermal ointment) and Zimeta™ (dipyrone injection) development programs and sponsoring scientific sessions. In addition, KindredBio will be sponsorin
May 24, 2017 10:01 am ET
Kindred Biosciences to Present at 7th Annual LD Micro Invitational
SAN FRANCISCO, May 24, 2017 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that Denise Bevers, Co-Founder and COO, will be presenting and hosting one-on-one investor meetings at the 7th Annual LD Micro Invitational in Los Angeles, CA on Tuesday, June 6, 2017 at 1:30 PM PST. The conference will be held at the Luxe Sunset Bel Air Hotel.
May 03, 2017 05:01 pm ET
Kindred Biosciences Announces First Quarter 2017 Financial Results
SAN FRANCISCO, May 3, 2017 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the first quarter ended March 31, 2017 and provided updates on its programs.  
May 01, 2017 08:02 am ET
Kindred Biosciences Announces Initiation of Enrollment in Pivotal Effectiveness Trial of Zimeta Oral for the Control of Fever in Horses
SAN FRANCISCO, May 1, 2017 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that the first patient has been enrolled in the pivotal effectiveness trial evaluating its novel, oral formulation of Zimeta™ (dipyrone oral gel) for the control of fever in horses.
Apr 24, 2017 09:32 am ET
Kindred Biosciences to Announce First Quarter 2017 Financial Results
SAN FRANCISCO, April 24, 2017 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will release its first quarter 2017 financial results on May 3, 2017 after the market close. The Company will host a conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time that day.
Mar 16, 2017 05:01 pm ET
Kindred Biosciences to Present at 2017 Jefferies Animal Health Summit
SAN FRANCISCO, March 16, 2017 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that Dr. Richard Chin, Chief Executive Officer, will be presenting at the 2017 Jefferies Animal Health Summit in New York, NY on Thursday, March 30, 2017 at 10:45 AM EDT. 
Mar 07, 2017 08:30 am ET
Kindred Biosciences Announces Global Sponsorship of International Society of Equine Locomotor Pathology
SAN FRANCISCO, March 7, 2017 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, is proud to announce its partnership with the International Society of Equine Locomotor Pathology (ISELP) by joining their team of Global Sponsors starting in 2017. The partnership with ISELP is part of an initiative by KindredBio to support the education of veterinarians and veterinary students, and to promote the growth and advancement of the equine industry. ISELP is an advanced education program for equine veterinarians to le
Mar 01, 2017 04:01 pm ET
Kindred Biosciences Announces Fourth Quarter and Year-End 2016 Financial Results
SAN FRANCISCO, March 1, 2017 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN) (KindredBio), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the fourth quarter and full year ended December 31, 2016.  
Feb 21, 2017 08:30 am ET
Kindred Biosciences to Announce Fourth Quarter and Year-End 2016 Financial Results
SAN FRANCISCO, Feb. 21, 2017 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will release its fourth quarter and year-end 2016 financial results on March 1, 2017 after the market close. The Company will host a conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time that day.
Feb 06, 2017 09:00 am ET
Kindred Biosciences Receives Early Approval of Effectiveness Technical Section from FDA for Mirataz™ New Animal Drug Application
SAN FRANCISCO, Feb. 6, 2017 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced it has received a technical section complete letter for effectiveness from the U.S. Food and Drug Administration's Center for Veterinary Medicine for Mirataz™ (mirtazapine transdermal ointment) approving the technical section. 
Nov 29, 2016 09:01 am ET
Kindred Biosciences to Present Zimeta Pivotal Data at the 62nd Annual American Association of Equine Practitioners Convention
SAN FRANCISCO, Nov. 29, 2016 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that Emily Sundman, DVM, Clinical Development Scientist for KindredBio, will present pivotal effectiveness data for Zimeta™ (dipyrone injection) at the American Association of Equine Practitioners (AAEP) Convention in Orlando, FL on Tuesday, December 6, 2016 at 8:25 AM ET as part of the Internal Medicine track. The presentation will be available at http://kindredbio.com/investor-relations/events/ following the AAE
Nov 18, 2016 09:01 am ET
Kindred Biosciences to Present at 9th Annual LD Micro Investor Conference
SAN FRANCISCO, Nov. 18, 2016 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that Dr. Richard Chin, President and CEO, will be presenting at the 9th Annual LD Micro Investor Conference in Los Angeles, CA on Wednesday, December 7, 2016 at 1:30 PM PT. The conference is being held at the Luxe Sunset Boulevard Hotel.
Nov 07, 2016 09:01 am ET
Kindred Biosciences Announces Third Quarter 2016 Financial Results
SAN FRANCISCO, Nov. 7, 2016 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the third quarter ended September 30, 2016 and provided updates on its programs.
Oct 24, 2016 10:01 am ET
Kindred Biosciences to Announce Third Quarter 2016 Financial Results
SAN FRANCISCO, Oct. 24, 2016 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will release its third quarter 2016 financial results on November 7, 2016 after the market close. The Company will host a conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time that day.
Oct 04, 2016 05:01 pm ET
Kindred Biosciences Receives Approval of Effectiveness Technical Section from FDA for Zimeta New Animal Drug Application
SAN FRANCISCO, Oct. 4, 2016 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced it has received a technical section complete letter for effectiveness from the U.S. Food and Drug Administration's Center for Veterinary Medicine for Zimeta™ (dipyrone injection) approving the technical section. 
Sep 30, 2016 10:01 am ET
Kindred Biosciences Submits Final Major New Animal Drug Application Technical Section for Safety for Mirataz to FDA and Launches KindredBio Equine Website
SAN FRANCISCO, Sept. 30, 2016 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the submission to FDA of the Safety technical section of the New Animal Drug Application (NADA) for Mirataz™ (mirtazapine 2% transdermal ointment, KIND-010). This is the final major technical section to be submitted for Mirataz. The Chemistry, Manufacturing, and Controls technical section was submitted in May 2016 and the Effectiveness technical section was submitted in August 2016.
Sep 20, 2016 05:01 pm ET
Kindred Biosciences to Present at 2016 Ladenburg Thalmann Healthcare Conference
SAN FRANCISCO, Sept. 20, 2016 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced Dr. Richard Chin, President and CEO, will be presenting at the Ladenburg Thalmann Healthcare Conference in New York City on Tuesday, September 27, 2016 at 11:00 AM EDT. The conference is being held at the Sofitel Hotel.
Sep 15, 2016 05:01 pm ET
Kindred Biosciences to Participate in a BIO Animal Biotech Summit Panel
SAN FRANCISCO, Sept. 15, 2016 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that Stephen Sundlof, DVM, PhD, Chief Scientific Officer and Executive Vice President, Regulatory Affairs and Quality, will be serving on a panel at the BIO Animal Biotech Summit in Bethesda, Maryland on Thursday, September 22, 2016 at 3.30pm EDT. The panel discussion, titled "Barriers to Innovation: Regulation and Politics," will discuss the role of regulation in facilitating or impeding technological innovation
Aug 22, 2016 05:01 pm ET
Kindred Biosciences Submits New Animal Drug Application Technical Section for Effectiveness for Mirataz to FDA
SAN FRANCISCO, Aug. 22, 2016 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the submission of the Effectiveness Technical Section of the New Animal Drug Application for Mirataz™ (mirtazapine transdermal ointment) to the Food and Drug Administration (FDA) for the management of weight loss in cats. The Chemistry, Manufacturing, and Controls Technical Section was submitted in May 2016 and the Company plans to submit the Safety Technical Section in the third quarter of 2016.
Aug 08, 2016 05:01 pm ET
Kindred Biosciences Announces Second Quarter 2016 Financial Results
SAN FRANCISCO, Aug. 8, 2016 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the second quarter ended June 30, 2016 and provided updates on its programs.  
Jul 26, 2016 05:02 pm ET
Kindred Biosciences to Announce Second Quarter 2016 Financial Results
SAN FRANCISCO, July 26, 2016 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will release its second quarter 2016 financial results on August 8, 2016 after the market close. The Company will host a conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time that day.
Jun 14, 2016 05:02 pm ET
Kindred Biosciences Announces Initiation of Pilot Field Study of Atopic Dermatitis and Other Updates
SAN FRANCISCO, June 14, 2016 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, announced the initiation of a pilot field study designed to test several molecules, including anti-cytokine antibodies, in dogs with atopic dermatitis.
May 25, 2016 05:05 pm ET
Kindred Biosciences Announces HITS Sponsorship
SAN FRANCISCO, May 25, 2016 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, is pleased to announce their Platinum Sponsorship of the HITS Horse Show series.  The sponsorship will start this week at the Saugerties, New York facility for the HITS-on-the-Hudson series and will extend through both the HITS Ocala Winter Circuit in Ocala, Florida, and the HITS Desert Circuit in Thermal, California.
May 16, 2016 09:30 am ET
Kindred Biosciences Announces Positive Results from Pivotal Study of KIND-010 for the Management of Weight Loss in Cats
SAN FRANCISCO, May 16, 2016 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive topline results from its pivotal field study of KIND-010, mirtazapine transdermal gel, for the management of weight loss in cats.
May 05, 2016 09:30 am ET
Kindred Biosciences Announces First Quarter 2016 Financial Results
SAN FRANCISCO, May 5, 2016 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the first quarter ended March 31, 2016 and provided updates on its programs.  
May 04, 2016 05:02 pm ET
Kindred Biosciences Submits KIND-010 New Animal Drug Application Technical Section for Chemistry, Manufacturing, and Controls to FDA
SAN FRANCISCO, May 4, 2016 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the submission to FDA of the Chemistry, Manufacturing, and Controls (CMC) technical section of the New Animal Drug Application for KIND-010. 
Apr 25, 2016 10:02 am ET
Kindred Biosciences to Announce First Quarter 2016 Financial Results
SAN FRANCISCO, April 25, 2016 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will release its first quarter 2016 financial results on May 5, 2016 after the market close. The Company will host a conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time that day.
Apr 15, 2016 10:02 am ET
Kindred Biosciences Elects Herbert D. Montgomery to Join Its Board of Directors
SAN FRANCISCO, April 15, 2016 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that Mr. Herbert Montgomery will be joining the Company's Board of Directors. Mr. Montgomery will serve as the Chairman of the Company's Audit Committee.
Mar 15, 2016 05:01 pm ET
Kindred Biosciences Submits Final Major New Animal Drug Application Technical Section for Safety for Zimeta to FDA
SAN FRANCISCO, March 15, 2016 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the submission to FDA of the Safety technical section of the New Animal Drug Application (NADA) for Zimeta™ (dipyrone injection, KIND-012).  This is the final major technical section to be submitted for Zimeta. The Chemistry, Manufacturing, and Controls technical section was submitted in December 2015 and the Effectiveness technical section was submitted in February 2016.
Mar 02, 2016 04:01 pm ET
Kindred Biosciences Announces Fourth Quarter and Year-End 2015 Financial Results
SAN FRANCISCO, March 2, 2016 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the fourth quarter and full year ended December 31, 2015.  
Feb 25, 2016 09:02 am ET
Kindred Biosciences to Announce Fourth Quarter and Year-End 2015 Financial Results
SAN FRANCISCO, Feb. 25, 2016 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will release its fourth quarter and year-end 2015 financial results on March 2, 2016 after the market close. The Company will host a conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time that day.
Feb 11, 2016 04:02 pm ET
Kindred Biosciences Submits Zimeta (KIND-012) New Animal Drug Application Technical Section for Effectiveness to FDA
SAN FRANCISCO, Feb. 11, 2016 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the submission to FDA of the Effectiveness Technical Section of the New Animal Drug Application (NADA) for Zimeta™ (dipyrone injection, KIND-012).  Positive topline results from the pivotal field study (KB0120) of Zimeta for the control of pyrexia (fever) in horses were recently reported by the Company.
Jan 26, 2016 09:02 am ET
Kindred Biosciences Releases Positive Results of Pilot Field Study of KIND-010 for the Management of Weight in Cats
SAN FRANCISCO, Jan. 26, 2016 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today released positive results from its pilot field study (KB104P) of KIND-010 for the management of weight in cats. It also announced successful completion of the sample size reassessment of the ongoing pivotal study.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.